Status:
COMPLETED
Phase II Study of Weekly Paclitaxel (BMS-181339)in Patients With Advanced or Recurrent Esophageal Cancer
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Esophageal Cancer
Eligibility:
All Genders
20+ years
Phase:
PHASE2
Brief Summary
The purpose of this clinical research study is to learn if BMS-181339 can shrink or slow the growth of the cancer in patients with advanced or recurrent esophageal cancer. The safety of this treatment...
Eligibility Criteria
Inclusion
- Patients must have measurable disease
- Patients must have experienced on pervious chemotherapy regime
- Men and Women, with the age 20 years or older
- ECOG PS: 0-1
Exclusion
- Patients with previous therapy with Taxanes
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2008
Estimated Enrollment :
53 Patients enrolled
Trial Details
Trial ID
NCT00344552
Start Date
June 1 2006
End Date
March 1 2008
Last Update
November 13 2009
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Nagoya, Aichi-ken, Japan, 464-8681
2
Local Institution
Kashiwa-Shi, Chiba, Japan, 277-0882
3
Local Institution
Sagamihara-Shi, Kanagawa, Japan, 228-8520
4
Local Institution
Osaka, Osaka, Japan